Pilgrim, whose device combines air sampling and genomic sequencing to detect biological threats, raised a $25M seed led by Buckley at a $150M valuation

If you need to detect airborne pathogens, the speed and accuracy of threat identification significantly improve.

Pilgrim, a company developing a portable device for detecting biological threats, has secured $25 million in seed funding. The investment was led by Buckley, valuing the company at $150 million. Pilgrim's technology integrates air sampling with genomic sequencing to rapidly identify dangerous biological agents. The 50-pound device aims to provide a rapid and on-site capability for threat detection. The funding round also saw participation from notable investors, including two leaders from Anthropic.

This funding round signals a growing investor confidence in advanced biosurveillance technologies that combine multiple detection modalities. Pilgrim's integrated approach, merging physical sampling with rapid genomic analysis, addresses a critical need for faster response to biological threats, moving beyond traditional laboratory-based methods. The participation of AI leaders from Anthropic may also indicate potential synergies between biological threat detection and advanced AI for pattern recognition and analysis in complex data streams.

The successful seed round at a substantial valuation highlights the market's demand for innovative solutions in biosecurity and public health preparedness. Pilgrim's device, if scalable and effective in real-world conditions, could redefine emergency response protocols and environmental monitoring. Future developments will likely focus on miniaturization, increasing the range of detectable threats, and integrating with broader public health alert systems, potentially creating new standards for threat detection capabilities.